Dr. Thomas J. Nero, M.D.
Interventional Cardiology (Interventional Cardiology Physician)
9 Healthcare Dr Ste 105
Biddeford, ME 04005
Who else practices at this address →
York County includes primary care (6% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 784
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
ME license MD18424 -
Cardiovascular Disease Physician
ME license MD18424 · NY license 2021412
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mainehealth Maine Medical Center Portland, ME
- Stamford Hospital Stamford, CT
- St Vincent's Medical Center Bridgeport, CT
Medical groups
- Mainehealth (2,633 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 784
- Services billed
- 3,506
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 930 | 471 |
| Established patient office or other outpatient visit, 30-39 minutes | 879 | 447 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 296 | 155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 259 | 243 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 101 | 99 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 98 | 96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 86 | 86 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 80 | 79 |
| New patient office or other outpatient visit, 30-44 minutes | 38 | 38 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Biddeford, ME | 287 |
| Ezetimibe Other prescribers in Biddeford, ME | 183 |
| Atorvastatin Calcium Other prescribers in Biddeford, ME | 142 |
| Metoprolol Succinate Other prescribers in Biddeford, ME | 115 |
| Amlodipine Besylate Other prescribers in Biddeford, ME | 86 |
| Eliquis (apixaban) Other prescribers in Biddeford, ME | 77 |
| Furosemide Other prescribers in Biddeford, ME | 71 |
| Repatha Sureclick (evolocumab) Other prescribers in Biddeford, ME | 64 |
| Losartan Potassium Other prescribers in Biddeford, ME | 56 |
| Xarelto (rivaroxaban) Other prescribers in Biddeford, ME | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $121 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $66.77 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $37.14 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $16.68 |
| Food and Beverage | $121 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $488,384 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
Janssen Research & Development, LLC - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
Janssen Research & Development, LLC - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.